A Phase 1B study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF-mutant metastatic melanoma (The CELEBRATE study) (NCT04720768)
CELEBRATE
This trial is No longer recruiting
Registration number NCT04720768
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Mark Shackleton
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR